What is Saccharomyces cerevisiae UFMG A-905 and how is it different from brewer's yeast?

S. cerevisiae UFMG A-905 is a specific probiotic strain of baker's/brewer's yeast isolated and characterized at the Federal University of Minas Gerais (UFMG) in Brazil, selected for its immunomodulatory properties. Unlike generic brewer's yeast used for nutritional supplementation, UFMG A-905 is studied as a live biotherapeutic agent targeting gut and immune health through specific receptor interactions, and its effects cannot be assumed equivalent to other S. cerevisiae products.

Can Saccharomyces cerevisiae UFMG A-905 help with ulcerative colitis?

Preclinical mouse studies (PMID: 26322540) showed that oral administration of S. cerevisiae UFMG A-905 reduced intestinal inflammation markers and improved colon histology scores in chemically induced colitis models. However, no human clinical trials have been conducted, so it is not possible to confirm efficacy or determine appropriate dosing for ulcerative colitis patients. Anyone with inflammatory bowel disease should consult a gastroenterologist before using any probiotic yeast supplement.

Does Saccharomyces cerevisiae UFMG A-905 reduce allergy symptoms?

Mouse models of allergic asthma demonstrated that UFMG A-905 administration reduced bronchial hyperresponsiveness and lowered Th2 cytokines IL-4 and IL-5 in airway tissue (PMIDs: 36445686, 28166610), suggesting an immunomodulatory effect on allergic inflammation. Similar mechanisms may theoretically apply to food allergy, but no controlled human trials have validated these findings. The strain's ability to engage Dectin-1 and shift immune balance toward regulatory responses is the proposed driver of these effects.

Is Saccharomyces cerevisiae UFMG A-905 safe for immunocompromised individuals?

Probiotic yeast strains including S. cerevisiae carry a small but real risk of causing fungemia (yeast in the bloodstream) in individuals with severely compromised immune systems, indwelling catheters, or critical illness. This risk, documented with related probiotic yeasts like S. boulardii, means that immunocompromised patients—including those on chemotherapy, organ transplant recipients, or people with advanced HIV—should avoid UFMG A-905 unless explicitly advised otherwise by their physician. No strain-specific safety trials have been published to quantify this risk for UFMG A-905.

What dosage of Saccharomyces cerevisiae UFMG A-905 has been studied?

Published preclinical studies have used specific colony-forming unit (CFU) doses administered orally to mice, but these animal dosages have not been scaled or validated for human use through clinical trials. No human dosing guidelines exist for UFMG A-905 specifically, and any commercial product dosing recommendations would be extrapolated rather than evidence-based. Until phase I/II human trials establish pharmacokinetic and safety parameters, there is no established effective or safe dose for human supplementation.

What does current clinical research show about Saccharomyces cerevisiae UFMG A-905's effectiveness in humans?

Most evidence for Saccharomyces cerevisiae UFMG A-905 comes from preclinical and animal studies, with limited human clinical trials published to date. Available research suggests potential benefits for intestinal inflammation and allergic responses, but these findings are primarily from laboratory and mouse models rather than large-scale human studies. More rigorous human trials are needed to establish clinical efficacy and safety profiles in patient populations.

Who should consider supplementing with Saccharomyces cerevisiae UFMG A-905 and who should avoid it?

This strain may benefit individuals with ulcerative colitis, allergic asthma, or food allergy-related inflammation based on preliminary research, though clinical evidence remains limited. However, immunocompromised patients, those with severe systemic infections, or individuals with yeast sensitivities should avoid this probiotic without medical supervision. Patients taking immunosuppressant medications should consult a healthcare provider before use due to the fungal nature of this organism.

How does Saccharomyces cerevisiae UFMG A-905 compare to other probiotic strains for inflammatory bowel conditions?

Saccharomyces cerevisiae UFMG A-905 is a yeast-based probiotic, whereas most IBD research focuses on bacterial strains like Lactobacillus and Bifidobacterium species. The yeast strain may offer unique advantages in reducing Th2 cytokines and bronchial hyperresponsiveness based on animal models, but direct comparative human studies between this strain and other probiotics are lacking. Choice of probiotic strain should be guided by individual condition and available clinical evidence.

Saccharomyces cerevisiae UFMG A-905

Saccharomyces cerevisiae UFMG A-905 is a probiotic yeast strain isolated in Brazil that modulates host immune responses primarily through interaction with pattern recognition receptors such as Toll-like receptors and Dectin-1, which recognize yeast cell wall components including beta-glucans and mannoproteins. Preclinical research suggests it may reduce intestinal inflammation and attenuate allergic airway responses by shifting cytokine profiles away from Th2-dominant immune activity.

Category: Fermented/Probiotic Evidence: 2/10 Tier: Emerging

Saccharomyces cerevisiae UFMG A-905 — Hermetica Encyclopedia

Origin & History

Saccharomyces cerevisiae UFMG A-905 is a specific yeast strain isolated and characterized by researchers at the Federal University of Minas Gerais (UFMG) in Brazil, primarily studied as a probiotic for immunomodulatory effects. It originates from natural yeast sources typical of S. cerevisiae and is propagated as live viable cells via standard microbial culture methods rather than chemical extraction.

Historical & Cultural Context

No evidence of traditional medicinal use exists for S. cerevisiae UFMG A-905, as it is a modern research strain from UFMG not documented in historical systems like Ayurveda, TCM, or folk medicine. While general S. cerevisiae (baker's/brewer's yeast) has longstanding food fermentation roles, this specific strain lacks traditional context.

Health Benefits

• May reduce intestinal inflammation in ulcerative colitis models (preclinical evidence only, PMID: 26322540)
• Potentially attenuates allergic asthma symptoms by reducing bronchial hyperresponsiveness and Th2 cytokines (mouse studies only, PMIDs: 36445686, 28166610)
• Could help manage food allergy-related tissue injury and local inflammation (preliminary animal data, PMID: 32264688)
• May protect against chemotherapy-induced intestinal damage in irinotecan mucositis (mouse model evidence, PMID: 27133563)
• Possible perinatal asthma prevention effects when administered during pregnancy/lactation (preclinical only, PMID: 39353595)

How It Works

S. cerevisiae UFMG A-905 cell wall components, particularly beta-1,3/1,6-glucans and mannoproteins, engage pattern recognition receptors including Dectin-1, TLR2, and TLR4 on dendritic cells and macrophages, triggering immunomodulatory signaling cascades. This receptor engagement promotes regulatory T cell activity and suppresses Th2-skewed cytokine production—specifically reducing IL-4, IL-5, and IL-13—while potentially upregulating anti-inflammatory IL-10 and IL-12 pathways. In intestinal models, the strain appears to reinforce epithelial barrier integrity and dampen NF-κB-mediated pro-inflammatory signaling, reducing inflammatory mediators implicated in ulcerative colitis pathology.

Scientific Research

All available evidence for S. cerevisiae UFMG A-905 comes from murine (mouse) models with no human clinical trials, RCTs, or meta-analyses identified. Key preclinical studies include mouse models of ulcerative colitis (PMID: 26322540), food allergy (PMID: 32264688), asthma (PMIDs: 36445686, 28166610), and chemotherapy-induced mucositis (PMID: 27133563), with sample sizes typically ranging from 5-10 mice per group.

Clinical Summary

Current evidence for S. cerevisiae UFMG A-905 is entirely preclinical, with no published human clinical trials as of the available literature. Mouse models of chemically induced ulcerative colitis (PMID: 26322540) demonstrated reduced intestinal inflammation and histological damage scores following oral administration of this strain. Separate murine allergic asthma models (PMIDs: 36445686, 28166610) reported attenuated bronchial hyperresponsiveness and decreased Th2 cytokines (IL-4, IL-5) in treated animals compared to controls. The absence of randomized controlled trials in humans means all purported benefits remain hypothesis-generating and cannot be reliably extrapolated to clinical practice.

Nutritional Profile

Saccharomyces cerevisiae UFMG A-905 is a probiotic yeast strain with a nutritional composition broadly consistent with Saccharomyces cerevisiae species characteristics, though strain-specific quantitative data remains limited in published literature. As a yeast biomass, it contains approximately 40-50% protein by dry weight, comprising all essential amino acids with notable concentrations of lysine (~7g/100g protein) and threonine (~5g/100g protein). Carbohydrate content ranges 30-40% dry weight, predominantly as beta-1,3/1,6-glucans (cell wall polysaccharides, ~30% of cell wall mass) and mannan-protein complexes; these beta-glucans are key immunomodulatory bioactive compounds with demonstrated receptor binding to Dectin-1 on immune cells. Fat content is low at 3-7% dry weight, primarily composed of unsaturated fatty acids including oleic acid (C18:1) and palmitoleic acid (C16:1). B-vitamin content is significant: thiamine (B1) ~1-10 mg/100g dry weight, riboflavin (B2) ~4-6 mg/100g, niacin (B3) ~30-60 mg/100g, pantothenic acid (B5) ~10-20 mg/100g, pyridoxine (B6) ~2-4 mg/100g, and folate ~1-3 mg/100g; B12 is absent as yeast cannot synthesize cobalamin. Mineral content includes zinc (~8-10 mg/100g), selenium (variable, strain/media dependent, ~0.1-0.5 mg/100g), chromium (naturally present as glucose tolerance factor complex), iron (~3-5 mg/100g), and phosphorus (~1.5-2g/100g predominantly as phytate, which may reduce bioavailability of co-ingested minerals). Cell wall trehalose (~1-3% dry weight) serves as a stress protectant relevant to viability during GI transit. Bioavailability note: when delivered as whole viable yeast cells, the cell wall matrix limits direct nutrient absorption; immunological and gut-modulatory effects are mediated primarily through pattern recognition receptor interactions (Dectin-1, TLR2) with beta-glucans and mannoproteins rather than systemic nutrient delivery. UFMG A-905 strain-specific metabolite profiling data is not yet publicly available beyond its probiotic characterization studies.

Preparation & Dosage

In mouse asthma models, daily gavage of 10^9 CFU/mL showed efficacy, while lower doses (10^7-10^8 CFU/mL) had limited effects. Alternate-day dosing of 10^9 CFU/mL (3x/week for 5 weeks) also showed benefits. No human dosage data is available as all studies are preclinical. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other probiotic yeasts, Lactobacillus strains, Bifidobacterium strains, Prebiotics (FOS/GOS), Vitamin D3

Safety & Interactions

As a Saccharomyces cerevisiae strain, UFMG A-905 is generally expected to share the safety profile of other probiotic yeasts, though strain-specific human safety data are not yet published. Individuals with yeast allergies, severely compromised immune systems (e.g., HIV/AIDS, post-transplant immunosuppression), or central venous catheters should avoid probiotic yeast supplementation due to rare but documented risks of fungemia in vulnerable populations. Potential interactions exist with antifungal medications such as fluconazole or itraconazole, which could reduce strain viability and effectiveness. Pregnancy and lactation safety has not been established for this specific strain, and use during these periods should only occur under medical supervision.